Tirzepatide (Zepbound) Titration for Obesity
Start tirzepatide at 2.5 mg subcutaneously once weekly, then increase the dose by 2.5 mg increments every 4 weeks (monthly) until reaching the maximum tolerated dose of 15 mg weekly. This monthly titration schedule minimizes gastrointestinal side effects while optimizing weight loss outcomes 1.
Standard Titration Schedule
The FDA-approved dosing regimen follows this algorithmic progression:
- Weeks 1-4: 2.5 mg once weekly (starting dose)
- Weeks 5-8: 5 mg once weekly
- Weeks 9-12: 7.5 mg once weekly
- Weeks 13-16: 10 mg once weekly
- Weeks 17+: 12.5 mg once weekly
- Maintenance: 15 mg once weekly (maximum dose)
The therapeutic doses approved for obesity treatment are 5 mg, 10 mg, and 15 mg weekly 1. The 2.5 mg dose serves as an initiation dose to allow physiologic adaptation and reduce gastrointestinal adverse events.
Key Principles for Titration
Always start treatment-naïve patients at the lowest dose (2.5 mg). This is essential to prevent clinically significant gastrointestinal side effects, which occur most commonly during dose escalation 1. The 2025 AACE guidelines explicitly state that "starting with the lowest dose is essential to prevent clinically significant side effects, and slow dose up-titration is vital in mitigating potential side effects" 1.
Increase doses monthly (every 4 weeks), not more frequently. This allows adequate time for the body to acclimate to each dose level given tirzepatide's long half-life of 116.7 hours 1.
Dose Optimization Strategy
Titrate to the maximum tolerated dose up to 15 mg weekly for optimal weight loss. The SURMOUNT-1 trial demonstrated dose-dependent efficacy: 15 mg achieved 22.5% weight loss, 10 mg achieved 19.5%, and 5 mg achieved 15.0% at 72 weeks 2, 1. Higher doses consistently produce superior outcomes for both weight reduction and cardiometabolic benefits.
However, recent evidence suggests that lower maintenance doses (2.5-5 mg) may be appropriate for select patients who achieve weight goals or experience intolerable side effects at higher doses 3, 4. A 2026 Japanese study found that 2.5 mg and 5 mg produced similar weight loss outcomes (-15.3% vs -16.1%) when combined with lifestyle modification, with better tolerability at 2.5 mg 3. The SURMOUNT-MAINTAIN trial demonstrated that reducing from maximum tolerated dose to 5 mg maintained significant weight loss (-16.6%) compared to placebo (-9.9%), though less than continuing maximum dose (-21.9%) 4.
Managing Side Effects During Titration
If gastrointestinal side effects occur, maintain the current dose for an additional 4 weeks before attempting further escalation. Do not advance to the next dose until symptoms resolve to mild or absent. The most common adverse events are nausea, diarrhea, vomiting, and constipation, occurring predominantly during dose escalation 1.
Counsel patients to:
- Avoid fatty foods that exacerbate symptoms
- Stop eating before feeling completely full
- Eat smaller portions more frequently rather than large meals
- Stay well-hydrated to prevent dehydration and renal impairment 1
Critical Pitfall: Treatment Interruption
If treatment is discontinued or paused for any significant length of time, restart at 2.5 mg and re-titrate upward. Patients cannot resume at their previous dose after an interruption—they must restart the titration schedule to allow the body time to re-acclimate 1. This is a commonly missed clinical detail that leads to severe gastrointestinal adverse events.
Long-Term Maintenance
Plan for indefinite treatment duration. Weight regain occurs rapidly upon discontinuation—the STEP 4 trial showed 6.9% weight regain during placebo administration after semaglutide discontinuation 2. The SURMOUNT-MAINTAIN trial confirmed that continuing tirzepatide at maximum tolerated dose maintained -21.9% weight loss at 112 weeks, while switching to placebo resulted in significant regain (only -9.9% from baseline) 4. Long-term use is necessary to maintain weight loss and associated cardiometabolic benefits.